<DOC>
	<DOC>NCT00355342</DOC>
	<brief_summary>This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones. The purpose of this study is to determine the effect of the steroid component of an inhaled product on bone mineral density in patients with Chronic Obstructive Pulmonary Disease (COPD).</brief_summary>
	<brief_title>Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUSÂ® Inhaler is a Trademark of the GSK Group of Companies.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criteria: Established clinical history of COPD. Baseline FEV1 &lt;70% predicted normal, and FEV1/FVC ratio of less than 70%. Smoking history of at least 10 packyears, where both current and former smokers will be eligible. Must have at least one native, evaluable hip. Exclusion criteria: History of or evidence for metabolic bone diseases other than osteoporosis or osteopenia.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Bone Mineral Density</keyword>
	<keyword>Osteopenia</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>COPD</keyword>
</DOC>